Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Genotypic correlates of a virologic response to stavudine after zidovudinemonotherapy
Autore:
Shulman, NS; Machekano, RA; Shafer, RW; Winters, MA; Zolopa, AR; Liou, SH; Hughes, M; Katzenstein, DA;
Indirizzi:
Stanford Univ, Med Ctr, Div Infect Dis, Stanford, CA 94305 USA Stanford Univ Stanford CA USA 94305 iv Infect Dis, Stanford, CA 94305 USA Harvard Univ, Stat & Data Anal Ctr, Boston, MA 02115 USA Harvard Univ Boston MA USA 02115 at & Data Anal Ctr, Boston, MA 02115 USA
Titolo Testata:
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
fascicolo: 4, volume: 27, anno: 2001,
pagine: 377 - 380
SICI:
1525-4135(20010801)27:4<377:GCOAVR>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIV-1 REVERSE-TRANSCRIPTASE; MUTATIONS CONFERRING RESISTANCE; HIGH-LEVEL RESISTANCE; PLUS DIDANOSINE; IMMUNODEFICIENCY; THERAPY; LAMIVUDINE; GENE; SUSCEPTIBILITY; EMERGENCE;
Keywords:
cross-resistance; drug resistance; genotype; stavudine; zidovudine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Shulman, NS Stanford Univ, Med Ctr, Div Infect Dis, 300 Pasteur Dr,S-156, Stanford, CA94305 USA Stanford Univ 300 Pasteur Dr,S-156 Stanford CA USA 94305 5 USA
Citazione:
N.S. Shulman et al., "Genotypic correlates of a virologic response to stavudine after zidovudinemonotherapy", J ACQ IMM D, 27(4), 2001, pp. 377-380

Abstract

Prior evidence suggests that resistance to zidovudine (ZDV) confers some degree of cross-resistance to stavudine (d4T), but no genotypic correlates of clinical d4T susceptibility and resistance exist. To identify the genotypic correlates of a virologic response to d4T, reverse transcriptase (RT) sequencing of archived plasma HIV isolates was performed on 31 subjects who received d4T monotherapy in the AIDS Clinical Trials Group 302 study, all ofwhom received more than 3 years of ZDV monotherapy. Baseline characteristics and all RT mutations were analyzed for impact on virologic suppression. Eight of 31 subjects (27%) achieved a virologic response of greater than 0.3 log reduction in plasma HIV RNA after 8 weeks of d4T. Responders were more likely to have lower median baseline viral loads (4.2 vs. 4.7; p = .01) and a trend toward fewer ZDV-associated mutations (median: I vs. 2; p = .09). No subject with greater than one ZDV mutation had a virologic response tod4T. Seven of the 8 responders had only a K70R mutation at baseline. We conclude that in patients with prior ZDV treatment. those with only one ZDV mutation, particularly at position 70, can still get reasonable virologic activity from d4T. Those with more mutations are not likely to have much benefit.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/06/20 alle ore 23:52:54